Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.

Authors:
Csizmarik A; Keresztes D; Nagy N; Bracht T; Sitek B and 12 more

Journal:
Int J Cancer

Publication Year: 2022

DOI:
10.1002/ijc.34159

PMCID:
PMC9539937

PMID:
35689436

Journal Information

Full Title: Int J Cancer

Abbreviation: Int J Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data availability statement the raw mass spectrometry data generated in this study have been deposited in the pride database with accession number pxd031847 ( http://www ebi ac uk/pride )."

Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST Boris Hadaschik reported consulting fees from Bayer, Janssen, Novartis, BMS, AstraZeneca, MSD, Pfizer, Amgen and Astellas. The other authors declare no potential conflicts of interest."

Evidence found in paper:

"Funding information János Bolyai Research Scholarship of the Hungarian Academy of Sciences; National Research, Development and Innovation Office, Grant/Award Number: NKFIH/FK 124431; New National Excellence Program of the Ministry for Innovation and Technology, Grant/Award Numbers: ÚNKP‐21‐3‐II‐SE‐13, ÚNKP‐21‐5‐SE‐3; Protein Research Unit Ruhr within Europe, Ministry of Innovation, Science and Research of North‐Rhine Westphalia, Germany"

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025